A shortage of BCG is foreseen till the end of 2013. Which will be the management of intermediate and high-risk NMI-BC if BCG will not be available? In patients harboring high-risk NMI tumors, particularly T1G3 and Tis, the first therapeutic choice is radical cystectomy. Device-assisted therapies, although showing promising results, should be considered only for selected patients. In intermediate risk patients, intravesical chemotherapy remains a legitimate option even if BCG is available. Thus, in a period of BCG shortage, intravesical chemotherapy should be offered, preferably preceded by early instillation, according to the EAU guidelines.
|Translated title of the contribution||[Endovesical treatment as an alternative to BCG for intermediate or high-risk NMI bladder cancer].|
|Number of pages||3|
|Volume||80 Suppl 21|
|Publication status||Published - 2013|
ASJC Scopus subject areas